Forte Biosciences, Inc. Announces 2025 Results and Provides Update Forte Biosciences (NASDAQ: FBRX) reported full-year 2025 results and a clinical update for FB102. R&D spending rose to $58.2M driven by Phase 2 celiac and multiple Phase 1b trials. Cash and equivalents were $77.0M at year-end with 12.9M shares outstanding.The company expects multiple FB102 topline readouts in 2026, including Phase 2 celiac results and Phase 1b readouts in vitiligo and alopecia areata.

#FBRX Forte Biosciences, Inc. Announces 2025 Results and Provides Update

www.stocktitan.net/news/FBRX/forte-bioscien...

Trade Alerts, Tuesday January 13, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Jan 13th - #XBIT #WLDN #SRTS #PPBT #MITK #KROS #ICHR #FBRX #ELE #DOGZ #CMTL #BBSI #ADAM #TDF #PSBD #MVO #YI #LEG #EVC #BW - More: crystalequityresearch.com/trade-alerts... - #smallcap

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update Forte Biosciences (NASDAQ: FBRX) reported Q3 2025 results and a clinical update on FB102 on November 14, 2025. The company said the U.S. IND is open and enrollment for the FB102 Phase 2 celiac disease trial has expanded to U.S. sites, with topline results expected in 2026. Two Phase 1b studies (vitiligo, alopecia areata) are ongoing with topline data expected in 1H26 and 2026, respectively. Q3 R&D expense was $15.2M and cash and equivalents were $93.4M as of September 30, 2025.

#FBRX Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

www.stocktitan.net/news/FBRX/forte-bioscien...

95% NK Cell Reduction: Forte's FB102 Drug Shows Breakthrough Results in Celiac Disease Clinical Trial FB102 demonstrated significant TCR γδ density reduction vs placebo (p=0.0007) in celiac disease trial. Phase 2 trial ongoing with topline data expected in 2026. Additional trials in vitiligo and alopecia planned.

#FBRX Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

www.stocktitan.net/news/FBRX/forte-bioscien...

Forte Advances Treatment Pipeline for Celiac Disease, Vitiligo, and Alopecia with $106M War Chest FB102 drug candidate progresses with Phase 2 celiac disease trial and two Phase 1b studies for vitiligo and alopecia. Company reports strong $106M cash position. Learn trial timelines.

#FBRX Forte Biosciences, Inc. Announces Results and Provides Update

www.stocktitan.net/news/FBRX/forte-bioscien...

Leading Indicators, Wednesday August 6, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Wed Aug 6th - #XTKG #TRUE #SEAT #RIGL #MDXH #LPSN #GO #FBRX #EHTH #DYN #CCLD #BTAI #AMWD #MBC #LANV #GB #CTEV #AGL - More: crystalequityresearch.com/leading-indi... - #smallcap

Forte Biosciences Announces Pricing of $75 Million Public Offering Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering. The offering consists of 5,630,450 shares of common stock priced at $12.00 per share, along with pre-funded warrants for up to 619,606 shares at $11.999 per warrant.The company has granted underwriters a 30-day option to purchase up to an additional 937,508 shares. The offering is expected to close around June 26, 2025. Forte plans to use the proceeds for working capital, clinical and preclinical development of its product candidate, and other research activities.

#FBRX Forte Biosciences Announces Pricing of $75 Million Public Offering

www.stocktitan.net/news/FBRX/forte-bioscien...

Forte Biosciences Announces Proposed Public Offering Forte Biosciences (Nasdaq: FBRX), a clinical-stage biopharmaceutical company, has announced a proposed public offering of common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares.The offering will be managed by TD Cowen, Evercore ISI, Guggenheim Securities, and Chardan as joint book-running managers, with Lucid Capital Markets as co-manager. Proceeds will be used for working capital, clinical and preclinical development of product candidates, and other research activities.

#FBRX Forte Biosciences Announces Proposed Public Offering

www.stocktitan.net/news/FBRX/forte-bioscien...

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study Forte Biosciences (NASDAQ: FBRX) reported positive Phase 1b trial results for FB102 in celiac disease treatment. The study enrolled 32 subjects (24 FB102, 8 placebo) who received 4 doses of FB102 (10 mg/kg) during a 16-day gluten challenge. FB102 showed statistically significant benefits in key metrics: composite histological VCIEL endpoint (p=0.0099), CD3-positive T cells density (p=0.0035), and a 73% improvement in Vh:Cd ratio compared to placebo. Patients treated with FB102 experienced 42% fewer GI symptoms during the gluten challenge. The treatment was well-tolerated with primarily mild adverse events and no grade 3 or higher SAEs. Following these positive results, Forte is initiating a Phase 2 trial with topline results expected in 2026. The company is also conducting FB102 trials for vitiligo, with results anticipated in H1 2026.

#FBRX Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

www.stocktitan.net/news/FBRX/forte-bioscien...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping up in trading, Tue May 27th - #SATL #MBAV #LUNR #FBRX #EU #DBVT #DGLY #VTEX #MTAL #ETWO - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Forte Biosciences, Inc. Announces Results and Provides Update Forte Biosciences (NASDAQ: FBRX) reported its Q1 2025 financial results and provided clinical updates. The company is advancing its FB102 drug candidate with ongoing trials in celiac disease and vitiligo, with topline data from the celiac disease trial expected this quarter. FB102 has shown good tolerability with no dropouts. Financial highlights include: R&D expenses increased to $12.7M (vs $4.4M in Q1 2024), primarily due to manufacturing and clinical trial costs. The company reported a net loss of $1.37 per share, improved from $4.03 in Q1 2024. Forte ended Q1 2025 with $45.9M in cash and cash equivalents, with 6.6M shares of common stock and 4.8M prefunded warrants outstanding.

#FBRX Forte Biosciences, Inc. Announces Results and Provides Update

www.stocktitan.net/news/FBRX/forte-bioscien...

Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest FB102 celiac trial advances with perfect retention rate. Forte strengthens position with $58.4M cash, reduced losses, and critical Q2 2025 data readout ahead.

#FBRX Forte Biosciences, Inc. Announces Results and Provides Clinical Update

www.stocktitan.net/news/FBRX/forte-bioscien...

NEWS: ( NASDAQ: #FBRX ) Forte Biosciences Inc. (NASDAQ: FBRX) Sees Notable Increase in Tuesday Morning Market Activity

#FBRX Forte Biosciences to Host R&D Day December 3, 2024

www.stocktitan.net/news/FBRX/forte-bioscien...

Reply To: Forex Forum November 20, 2024 at 9:04 pm #14759 Belgrade BobbyKeymaster Forte Biosciences – FBRX Forte Biosciences soars; company says private placement of $53 mln shares oversubscribed If we had some inside info...

global-view.com/forums/reply...
#Forte Biosciences – #FBRX
Forte Biosciences soars; company says private placement of $53 mln shares oversubscribed
If we had some inside info 😀
More on Global-view.com :) #stocks #index #forex #forexforum #forexlive #analytics

BREAKING NEWS: ( NASDAQ: #FBRX ) Forte Biosciences Inc. (NASDAQ: FBRX) Highlighted for Surprising Price Action

#StockMarket #News

JUST IN: ( NASDAQ: #FBRX ) Forte Biosciences Reports Oversubscribed $53 Million Private Placement to Advance FB102

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #FBRX ) Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

#StockMarket #News

#FBRX Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

www.stocktitan.net/news/FBRX/forte-bioscien...

News; ( NASDAQ: #FBRX ) FBRX announced stock split 1-25

#StockMarket #News